{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.666.5.2350","meta":{"versionId":"12","lastUpdated":"2016-03-31T01:00:12.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350","version":"20160331","name":"Immunocompromised Therapies I9","status":"active","date":"2016-03-31T01:00:12-04:00","publisher":"Lantana EH Steward","compose":{"include":[{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","concept":[{"code":"00.10","display":"Implantation of chemotherapeutic agent"},{"code":"00.15","display":"High-dose infusion interleukin-2 [IL-2]"},{"code":"17.70","display":"Intravenous infusion of clofarabine"},{"code":"99.25","display":"Injection or infusion of cancer chemotherapeutic substance"},{"code":"99.28","display":"Injection or infusion of biological response modifier [BRM] as an antineoplastic agent"}]}]},"expansion":{"identifier":"urn:uuid:e77a18bf-739a-40bc-8fbc-166f1f6554db","timestamp":"2022-06-10T08:40:10-04:00","total":5,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"00.10","display":"Implantation of chemotherapeutic agent"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"00.15","display":"High-dose infusion interleukin-2 [IL-2]"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"17.70","display":"Intravenous infusion of clofarabine"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"99.25","display":"Injection or infusion of cancer chemotherapeutic substance"},{"system":"http://hl7.org/fhir/sid/icd-9-cm","version":"2013","code":"99.28","display":"Injection or infusion of biological response modifier [BRM] as an antineoplastic agent"}]}}